Literature DB >> 6112769

Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal.

K J Zander, B Fischer, R Zimmer, M Ackenheil.   

Abstract

In 17 chronic schizophrenic patients under chronic neuroleptic treatment for 13 years, a 30-day drug withdrawal resulted in early relapse of four patients, slight deterioration in five, and slight amelioration in eight patients. No incidence of neuroleptic symptoms such as tardive dyskinesia occurred. Prolactin in plasma and cerebrospinal fluid (CSF), not being elevated under chronic treatment, decreased significantly after 30 days of withdrawal. Homovanillic acid and 3-methoxy-4-hydroxyphenylglycol in CSF ranged normally and did not change during withdrawal. In contrast, plasma noradrenaline was elevated and decreased after drug discontinuation. No unequivocal relationship between biochemical and psychopathological features was found.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112769     DOI: 10.1007/bf00431099

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

1.  Acute and chronic treatment with neuroleptics: similarities and differences in their action on nigrostriatal, mesolimbic, and mesocortical dopaminergic neurons.

Authors:  L Julou; B Scatton; J Glowinski
Journal:  Adv Biochem Psychopharmacol       Date:  1977

2.  Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients.

Authors:  R M Post; F K Goodwin
Journal:  Science       Date:  1975-10-31       Impact factor: 47.728

3.  Serum prolactin and clinical state during neuroleptic treatment and withdrawal.

Authors:  T P Laughren; W A Brown; B W Williams
Journal:  Am J Psychiatry       Date:  1979-01       Impact factor: 18.112

4.  [Lifestyle and age of schizophrenics. A catamnestic long-term study into old age].

Authors:  L Ciompi; C Müller
Journal:  Monogr Gesamtgeb Psychiatr Psychiatry Ser       Date:  1976

5.  3 -Methoxy- 4 -hydroxyphenylethylene glycol in human cerebrospinal fluid.

Authors:  E K Gordon; J Oliver
Journal:  Clin Chim Acta       Date:  1971-11       Impact factor: 3.786

6.  An experimental model of tardive dyskinesia.

Authors:  H L Klawans; R Rubovits
Journal:  J Neural Transm       Date:  1972       Impact factor: 3.575

7.  Gamma-aminobutyric acid in the brain in schizophrenia.

Authors:  A J Cross; T J Crow; F Owen
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

8.  Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain.

Authors:  I J Farley; K S Price; E McCullough; J H Deck; W Hordynski; O Hornykiewicz
Journal:  Science       Date:  1978-04-28       Impact factor: 47.728

9.  A radioimmunoassay for human prolactin.

Authors:  P Hwang; H Guyda; H Friesen
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

10.  Postsynaptic supersensitivity in schizophrenia.

Authors:  G N Pandey; D L Garver; C Tamminga; S Ericksen; S I Ali; J M Davis
Journal:  Am J Psychiatry       Date:  1977-05       Impact factor: 18.112

View more
  7 in total

1.  A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966-1993.

Authors:  Adil E Shamoo; Dianne N Irving; Patricia Langenberg
Journal:  Sci Eng Ethics       Date:  1997-10       Impact factor: 3.525

2.  Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study.

Authors:  Yu-Tao Xiang; Chuan-Yue Wang; Yong-Zhen Weng; Qi-Jing Bo; Helen F K Chiu; Sandra S M Chan; Edwin H M Lee; Gabor S Ungvari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-11-03       Impact factor: 4.328

3.  Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.

Authors:  G Bagdy; A Perényi; E Frecska; K Révai; Z Papp; M I Fekete; M Arató
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology.

Authors:  F Müller-Spahn; M Ackenheil; M Albus; C Botschev; D Naber; D Welter
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 5.  Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in schizophrenia and Parkinson's disease.

Authors:  Giulio Scigliano; Gabriele Ronchetti; Floriano Girotti
Journal:  Neurol Sci       Date:  2008-04-01       Impact factor: 3.307

Review 6.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

7.  Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.

Authors:  Giulio Scigliano; Gabriele Ronchetti
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.